This CME/CNE program will highlight recent advances in the treatment and management of breast cancer, as presented at the 40th Annual San Antonio Breast Cancer Symposium in San Antonio, Texas. Three expert faculty will review the pathophysiology of breast cancer and the rationale for therapeutic choices. An evaluation of recent clinical trial data of current and emerging therapies will be discussed. The faculty will also review how to implement effective individualized treatment plans with the healthcare team to improve patient outcomes. Upon completion of this activity, learners will gain knowledge on how to better care for patients with breast cancer, ultimately improving patient outcomes.
Oncologists, internists, nurse practitioners, nurses, and other healthcare professionals involved in the management of patients with breast cancer.
Upon completion of this activity, participants will be better able to do the following:
- Discuss the pathophysiology of breast cancer and the rationale for therapeutic choices.
- Analyze recent clinical trial data of current and emerging therapies for the treatment of breast cancer as presented at SABCS 2017.
- Integrate more effective individualized treatment regimens with the healthcare team to improve outcomes in patients with breast cancer.
Eric P. Winer, MD
Chief Clinical Strategy Officer
Director, Breast Oncology Center, Susan F. Smith Center for Women’s Cancers
Professor of Medicine, Harvard Medical School
Ian E. Krop, MD, PhD
Chief of Breast Medical Oncology
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Jennifer McKenna, RN, MSN, AOCNP
Dana-Farber Cancer Institute
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Eric P. Winer, MD (Chair)||Consultant/Advisor: Genentech, Inc.; Leap Therapeutics, Inc.; Tesaro, Inc.|
|Ian E. Krop, MD, PhD||Consultant/Advisor: Daiichi Sankyo Company, Limited; Genentech, Inc.; Roche; Seattle Genetics, Inc.Grant/Research Support: Genentech, Inc.; Roche|
|Jennifer McKenna, RN, MSN, AOCNP||Nothing to disclose|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Emma Gilmartin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.5 CNE contact hours (1.5 CNE pharmacotherapeutic contact hours).
This activity has been supported by an independent educational grant from Eisai Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Eisai Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
- Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
- 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].